Prospects for gene therapy in inherited neurodegenerative diseases

Current Opinion in Neurology

Volumn 20, Issue 2, 2007, Pages 151-158

  Cardone, Monica ^a  

^a TELETHON INSTITUTE OF GENETICS AND MEDICINE TIGEM   (Italy)

Author keywords

Central nervous system; Gene therapy; Neurodegenerative disease; Viral vector

Indexed keywords

4 HYDROXYTAMOXIFEN; ALPHA MANNOSIDASE; AMYLOID BETA ANTIBODY; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; ANTIBODY; AROMATIC LEVO AMINO ACID DECARBOXYLASE; BETA GLUCURONIDASE; CREATININE RECOMBINASE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE I; LENTIVIRUS VECTOR; LEVO IDURONIDASE; LEVODOPA; MEMBRANE METALLOENDOPEPTIDASE; NERVE GROWTH FACTOR; PARKIN; PARVOVIRUS VECTOR; SMALL INTERFERING RNA; TRIPEPTIDYL 1 PEPTIDASE; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; CELL TRANSPLANTATION; CELLULAR IMMUNITY; CHOLINERGIC NERVE CELL; CLINICAL TRIAL; COGNITIVE DEFECT; CONTINUOUS INFUSION; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; DRUG EFFECT; DYSKINESIA; ENCEPHALITIS; FIBROBLAST; GENE INDUCTION; GENE TARGETING; GENE THERAPY; GENETIC DISORDER; GENETIC TRANSDUCTION; HALLUCINATION; HUMAN; IMMUNIZATION; LYSOSOME STORAGE DISEASE; MANNOSIDOSIS; MEMORY DISORDER; MORQUIO SYNDROME; MUCOPOLYSACCHARIDOSIS TYPE 7; NERVE CELL DEGENERATION; NEURONAL CEROID LIPOFUSCINOSIS; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PROTEIN EXPRESSION; REVIEW; VIRAL GENE THERAPY;

ANIMALS; GENE THERAPY; HUMANS; NEURODEGENERATIVE DISEASES;

EID: 33947155703     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/WCO.0b013e32809f97ff     Document Type: Review

References (65)

1. Davidson BL, Breakefield XO. Viral vector for gene delivery to the nervous system. Nat Rev Neurosci 2003; 4:353-364.
2. Carter BJ. Adeno-associated virus vectors in clinical trials. Hum Gene Ther 2005; 16:541-550.
3. Terry RD, Masliah E, Salmon DP, et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991; 30:572-580.
4. Bartus RT, Dean R, Beer B, Lippa AS. The cholinergic hypoyhesis of geriatric memory dysfunction. Science 1982; 217:408-417.
5. Mandel RJ, Gage FH, Clevenger DG, et al. Nerve Growth Factors expressed in the medial septum following in vivo gene delivery using a recombinant adeno-associated viral vector protects cholinergic neurons from fimbria-fornix lesion-induced degeneration. Exp Neurol 1999; 155:59-64.
6. Klein RL, Hirko AC, Meyers CA, et al. NGF gene transfer to intrinsic basal forebrain neurons increases cholinergic cell size and protects from age-related, spatial memory deficits in middle-aged rats. Brain Res 2000; 875:144-151.
7. Tuszynski MH, Blesch A. NGF: from animal models of cholinergic neuronal degeneration to gene therapy in AD. Prog Brain Res 2004; 146:441-449.
8. Tuszynski MH, Thal L, Pay M, et al. A phase I clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 2005; 11:551-555.
9. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the Parkinson's disease APP mouse. Nature 1999; 400:173-177.
10. Morgan D, Diamond DM, Gottschall PE, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nat 2000; 408:982-985.
11. Orgogozo JM, Gilman S, Dartigues JF, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003; 61:46-54.
12. Ferrer I, Boada RM, Sanchez Guerra ML, et al. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol 2004; 14:11-20.
13. Zhang J, Wu X, Qin C, et al. A novel recombinant adeno-associated virus vaccine reduces behavioral impairment and beta-amyloid plaque in a mouse model of AD. Neurobiol Dis 2003; 14:365-379.
14. Hara H, Monsonego A, Yuasa K, et al. Development of a safe oral Abeta vaccine using recombinat adeno-associated virus vector for AD. J Alzheimers Dis 2004; 6:483-488.
15. Fukuchi K, Tahara K, Kim HD, et al. Anti-Abeta single-chain antibody delivery via adeno-associated virus for treatment of Alzheimer's disease. Neurobiol Dis 2006; 23:502-511.
16. Hong CS, Goins WF, Goss JR, et al. Herpex simplex virus RNAi and neprilysin gene transfer vectors reduce accumulation of AD related amyloid-β peptide in vivo. Gene Ther 2006; 13:1068-1079.
17. Hardy J. Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci 1997; 20:154-159.
18. Mochizuki H, Mizuno Y. Gene therapy for Parkinson's disease. J Neural Transm Suppl 2003; (65):205-213.
19. Muramatsu S, Fujimoto K, Ikeguchi K, et al. Behavioral recovery in a primate model of Parkinson's disease by triple transduction of striatal cells with adeno-associated virus vectors expressing dopamine-synthesizing enzymes. Hum Gene Ther 2002; 13:345-354.
20. Sanchez-Pernaute R, Harvey-WJ, Cunningham J, Bankiewicz KS. Functional effect of adeno-associated virus mediated gene transfer of aromatic L-amino acid decarboxylase into the striatum of 6-OHDA-lesioned rats. Mol Ther 2001; 4:324-330.
21. Bankiewicz KS, Eberling JL, Kohutnicha M, et al. Convection-enhanced dekivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. Exp Neurol 2000; 164:2-14.
22. Bankiewicz KS, Forsayeth J, Eberling JL. Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. Mol Ther 2006; 14:564-570. • Recovery in L-Dopa-dependent dopamine synthesis following by AAVh-AADC delivery in the striatum of MPTP-lesioned monkey has been already reported for the short term. The authors showed the effect of AAV-hAADC infusion in at least 6 years of transgene expression and they observed improvement of adverse side effects due to overexpression of L-Dopa.
23. Li XG, Okada T, Kodera M, et al. Viral-mediated temporally controlled dopamine production in a rat model of Parkinson disease. Mol Ther 2006; 13:160-166.
24. Grondin R, Zhang Z, Yi A, et al. Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkey. Brain 2002; 125:2191-2201.
25. Iravani MM, Costa S, Jackson MJ, et al. GDNF reverses priming for dyskinesia in MPTP-treated, L-Dopa-primed common marmosets. Eur J Neurosci 2001; 13:597-608.
26. Kirik D, Georgievska B, Rosenbland C, et al. Delayed infusion of GDNF promotes recovery of motor function in the partial lesion model of Parkinson's Disease. Eur J Neurosci 2001; 13:1589-1599.
27. Nutt JC, Burchiel KJ, Comella CL, et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 2003; 60:69-73.
28. Gill SS, Patel NK, Hotton GR, et al. Direct brain infusion of glia cell-line derived neurotrophic factor in Parkinson disease. Nat Med 2003; 9:589-595.
29. Kozlowski DA, Connor B, Tillerson JL, et al. Delivery of a GDNF gene into the substantia nigra after progressive 6-OHDA lesions maintains functional nigrostriatal connections. Exp Neurol 2000; 166:1-15.
30. Do Thi NA, Saillour P, Ferrero L, et al. Delivery of a GDNF by an E1, E3/E4 deleted adenoviral vector and driven by a GDNF promoter prevents dopaminergic neuron degeneration in a rat model of Parkinson's disease. Gene Ther 2004; 11:746-756.
31. Mandel RJ, Spratt SK, Sydney RO, Leff SE. Midbrain injection of recombinant adeno-associated virus encoding rat glia cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats. Proc Natl Acad Sci U S A 1997; 94:14083-14088.
32. Mandel RJ, Sydney RO, Leff SE. Recombinant adeno-associated viral vector-mediated glia cell line-derived neurotrophic facor gene transfer protects nigral dopaminergic neurons after onset of progressive degeneration in a rat model of Parkinson's disease. Exp Neurol 1999; 160:205-214.
33. Kirik D, Rosenbland C, Bjorklund A. Preservation of a functional nigrostriatal dopamine pathway by GDNF in the intrastriatal 6-OHDA lesion model depends on the site of administration of the trophic factor. Eur J Neurosci 2000; 12:3871-3882.
34. Wang L, Muramatsu S, Lu Y, et al. Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease. Gene Ther 2002; 9:381-389.
35. Eslamboli A, Cummings RM, Ridley RM, et al. Recombinant adeno-associated viral vector (rAAV) delivery of GDNF provides protection against 6-OHDA lesion in the common marmoset monkey (Callitrix Jacchus). Exp Neurol 2003; 184:536-548.
36. Kordower JH, Emborg ME, Bloch J, et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 2000; 290:767-773.
37. Georgievska B, Kirik D, Rosenbland C, et al. Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector. NeuroReport 2002; 13:75-82.
38. Bensadoun JC, Deglon N, Tseng JL, et al. Lentiviral vectors as a gene delivery system in the mouse mid-brain: cellular and behavioral improvement in a rat model of Parkinson' s disease using GDNF. Exp Neurol 2000; 164:15-24.
39. Kordower JH. In vivo gene therapy of glia cell-line derived neurotrophic factor for Parkinson's disease. Ann Neurol 2003; 53:S120-S134.
40. Brizard M, Carcenac C, Bemelmans AP, et al. Functional reinnervation from remaining DA terminals induced by GDNF lentivirus in a rat model of early Parkinson's disease. Neurobiol Dis 2006; 21:90-101.
41. Gasser T. Genetics of Parkinson's disease. Curr Opin Neurol 2005; 18:363-369.
42. Mata IF, Lockhart PJ, Farrer MJ. Parkin genetics: one model for Parkinson's disease. Hum Mol Genet 2004; 13:R127-R133.
43. Lo Bianco C, Schneider BL, Bauer M, et al. Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease. Proc Natl Acad Sci U S A 2004; 101:17510-17515.
44. Greene JC, Whitworth AJ, Kuo I, et al. Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proc Natl Acad Sci U S A 2003; 100:4078-4083.
45. Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular basis of inherited disease. New York: McGraw-Hill; 2001. pp. 4312-4352.
46. Meikle PJ, Hopwood JJ, Clauge AE, Carey WF. Prevalence of lysosomal enzyme. JAMA 1999; 281:294-254.
47. Ellinwood NM, Charles HV, Haskins ME. Gene therapy for lysosomal storage disease: the lesson and promise of animal models. J Gene Med 2004; 350:1960-1969.
48. Davidson BL, Stein CS, Heth JA, et al. Recombinant adeno-associated virus type 2, 4, and 5 vectors: Trasduction of variant cell types and regions in the mammalian central nervous system. Proc Natl Acad Sci U S A 2000; 97:3428-3432.
49. Broekman MLD, Comer LA, Hyman BT, Sena-Esteves M. 2006 Adeno-associated virus vectors serotyped with AAV8 capsid are more efficient than AAV-1 or -2 serotypes for widespread gene delivery to the neonatal mouse brain. Neuroscience 2006; 138:501-510.
50. Skorupa AF, Fisker KJ, Wilson JM, et al. Sustained production of β-glucuronidase from localized site after AAV vector gene transfer results in widespread distribution of enzyme and reversal of lysosomal storage lesion in a large volume of brain in mucopolissacharidosis VII mice. Exp Neurol 1999; 160:17-27.
51. Bosch A, Perret E, Desmaris N, Heard JM. Long-term and significant correction of brain lesions in adult mucopolysaccharidosis type VII mice using recombinant AAV vectors. Mol Ther 2000; 1:63-70.
52. Sferra TJ, Qu G, McNeely D, et al. Recombinant adeno-associated virus mediated correction of lysosomal storage within the central nervous system of the adult mucopolysacharidosis VII mouse. Hum Gene Ther 2000; 11:507-519.
53. Vite CH, McGowan JC, Sumit NN, et al. Effective gene therapy for an inherited CNS disease in a large animal model. Ann Neurol 2005; 57:355-364.
54. Ciron C, Desmaris N, Colle MA, et al. Gene therapy of the brain in the dog model of Hurler' syndrome. Ann Neurol 2006; 60:204-213.
55. Desmaris N, Verot L, Puech JP, et al. Prevention of neuropathology in the mouse model of Hurler syndrome. Ann Neurol 2004; 56:68-76.
56. Chen F, Vitry S, Hocquemiller M, et al. α-L-Iduronidase transport in neuritis. Mol Genet Metab 2006; 87:349-358.
57. Fu H, Samulski RJ, Mc Cown YI, et al. Neurological correction of lysosomal storage in a mucopolysaccharidosis IIIb mouse model by adeno-associated virus-mediated gene delivery. Mol Ther 2002; 5:42-49.
58. Crystal RG, Sondhi D, Hackett NR, et al. Clinical protocol. Administration of a replication-deficient adeno-associated virus gene transfer vector expressing the human CLN2 cDNA to the brain of children with late infantile neuronal ceroid lipofuscinosis. Hum Gene Ther 2004; 15:1131-1154.
59. Elliger SS, Elliger CA, Aguilar CP, et al. Elimination of lysosomal storage in brains of MPSVII mice treated by intrathecal administration of an adeno-associated virus vector. Gene Ther 1999; 6:1175-1178.
60. Elliger SS, Elliger CA, Lang C, Watson G. Enhanced secretion and uptake of b-glucoronidase improves adeno-associated viral-mediated gene therapy of mucopolysaccharidosis type VII mice. Mol Ther 2002; 5:617-626.
61. Liu G, Martins IH, Chiorini JA, Davidson BL. Adeno associated virus type 4 (AAV4) targets ependyma and astrocyte in the subventricular zone and RMS. Gene Ther 2005; 12:1503-1508.
62. Liu G, Martins IH, Wemmie JA, et al. Functional correction of CNS phenotypes in a lysosomal storage disease model using adeno-associated virus type 4 vectors. J Neurosci 2005; 41:9321-9327.
63. Cardone M, Polito VA, Pepe S, Mann L, et al. Correction of Hunter syndrome in the MPSII mouse model by AAV2/8-mediated gene delivery. Hum Mol Genet 2006; 15:1225-1236.
64. Roces DP, Lullmann-Rauch R, Peng J, et al. Efficacy of enzyme replacement therapy in alpha-mannosidosis mice: a preclinical animal study. Hum Mol Genet 2004; 13:1979-1988.
65. Vogler C, Levy B, Grubb JH, et al. Overcoming the blood-brain barrier with high-dose enzyme replacement therapy in murine mucopolysaccharidosis VII. Proc Natl Acad Sci U S A 2005; 102:14777-14782.